Our present study demonstrated that in insulin-treated patients with T2D, GLP-1 RA therapy was associated with a significantly lower risk of all-cause mortality compared with DPP-4 inhibitors and sulfonylureas. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.